Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

被引：0
作者：
S Bowyer
P Prithviraj
P Lorigan
J Larkin
G McArthur
V Atkinson
M Millward
M Khou
S Diem
S Ramanujam
B Kong
E Liniker
A Guminski
P Parente
M C Andrews
S Parakh
J Cebon
G V Long
M S Carlino
O Klein
机构：
[1] Rockingham General Hospital,Department of Medical Oncology
[2] School of Medicine and Pharmacology,undefined
[3] University of Western Australia,undefined
[4] Olivia Newton- John Cancer Centre,undefined
[5] Austin Hospital,undefined
[6] Heidelberg,undefined
[7] Olivia Newton-John Cancer Research Institute,undefined
[8] Heidelberg,undefined
[9] The Christie NHS Foundation Trust and University of Manchester,undefined
[10] Royal Marsden Hospital NHS Foundation Trust,undefined
[11] Peter MacCallum Cancer Centre,undefined
[12] Princess Alexandra Hospital,undefined
[13] Greenslopes Private Hospital,undefined
[14] Sir Charles Gairdner Hospital,undefined
[15] Westmead Hospital,undefined
[16] Melanoma Institute Australia,undefined
[17] Box Hill Hospital,undefined
[18] University of Sydney,undefined
来源：
British Journal of Cancer | 2016年 / 114卷
关键词：
metastatic melanoma; ipilimumab; pembrolizumab; nivolumab; immune-mediated adverse event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1084 / 1089
页数：5
相关论文
共 376 条
[1]  
Brahmer JR(2010)Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 3167-3175
[2]  
Drake CG(2015)Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma Melanoma Res 25 178-179
[3]  
Wollner I(2015)Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes J Immunol 194 950-959
[4]  
Powderly JD(2015)Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001 J Clin Oncol 33 9005-6688
[5]  
Picus J(2007)Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin Cancer Res 13 6681-247
[6]  
Sharfman WH(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-720
[7]  
Stankevich E(2015)Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma Clin Cancer Res 21 712-144
[8]  
Pons A(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-723
[9]  
Salay TM(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-377
[10]  
McMiller TL(2013)Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy Cancer Immunol Res 1 373-322
12345678910